Roche and Agilent Technologies, Inc. announced the signing of an exclusive agreement to provide continued service to NimbleGen microarray customers as Roche phases-out its NimbleGen array production and services. Researchers using NimbleGen microarrays for all applications, including comparative genomic hybridization, chromatin immunoprecipitation-on-chip, DNA methylation, and gene expression can transition to Agilent arrays, effective immediately, with minimal disruption. The similarities of the technologies and products from both companies provide an optimal transition path and the ability to run Agilent microarrays on the NimbleGen MS 200 Microarray Scanner.
“This global collaboration provides our customers with a confident and straightforward solution to move from NimbleGen to Agilent microarrays,” said Dan Zabrowski, Head of Roche Applied Science. “With Agilent as a leading global supplier of microarray technology, we are convinced researchers will be provided with the highest compatibility to NimbleGen products and services, and believe that they will continue to receive the exceptional service and support they have come to expect.”
“We are working closely with Roche to help customers make the transition to Agilent microarray products,” said Robert Schueren, vice president and general manager of Agilent’s Genomics Systems Division. “Our field service personnel are working directly with individual researchers to help convert their NimbleGen designs, and they will continue to provide enhanced service and support throughout the transition period and beyond. Additionally, Agilent is also enabling customers to read their arrays on NimbleGen scanners, eliminating the need to invest in capital equipment.”